Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + vinorelbine + zenocutuzumab
- Development stage
- Unknown
- Lead developer
- Merus
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of trastuzumab (a HER2-targeted monoclonal antibody), vinorelbine (a chemotherapeutic agent), and zenocutuzumab (a bispecific antibody targeting HER2 and HER3). This combination is being investigated for the treatment of HER2-positive metastatic breast cancer. Trastuzumab targets the HER2 receptor to inhibit tumor growth, vinorelbine is a vinca alkaloid chemotherapy that disrupts microtubule formation, and zenocutuzumab employs a "Dock & Block" mechanism to inhibit NRG1-activated HER2/HER3 oncogenic signaling.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)Microtubule
Beyond the preview
Go deeper on trastuzumab + vinorelbine + zenocutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + vinorelbine + zenocutuzumab.